Sugi Predict

Sugi Predict / Compounds / SCHEMBL3936113

SCHEMBL3936113

SCHEMBL3936113

C#Cc1cccc(N2CC(C)(C)C2=O)c1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 1/20 0.74
▸ ALDH1A1 P00352 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ RECQL P46063 1/20 0.46
▸ GAA P10253 2/20 0.45
▸ L3MBTL1 Q9Y468 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ GRM5 P41594 1/20 0.43
▸ POLB P06746 1/20 0.41
▸ LMNA P02545 1/20 0.39
▸ EGFR P00533 2/20 0.38
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17870951 0.73 ALDH1A1 (0.45) NSD2ALDH1A1SMN1; SMN2RAB9AGAA
SCHEMBL8577305 0.73 ALDH1A1 (0.61) NSD2ALDH1A1SMN1; SMN2RAB9AGAA
SCHEMBL23120599 0.72 CRBN (0.64) NSD2ALDH1A1KDM4ELMNA
SCHEMBL22745913 0.69 ELANE (0.39) NSD2LMNAEGFRCA12CA1
SCHEMBL9468866 0.67 MGLL (0.64) ALDH1A1L3MBTL1LMNAEGFRCA12
SCHEMBL3935908 0.67 SMN1; SMN2 (0.59) NSD2ALDH1A1SMN1; SMN2RAB9ARECQL
SCHEMBL1208088 0.66 SMN1; SMN2 (0.84) NSD2ALDH1A1SMN1; SMN2RAB9ARECQL
SCHEMBL12584934 0.66 SMN1; SMN2 (0.84) NSD2ALDH1A1SMN1; SMN2RAB9ARECQL
SCHEMBL2518327 0.65 ALDH1A1 (0.41) NSD2ALDH1A1SMN1; SMN2RAB9ARECQL
SCHEMBL6208384 0.65 KDM4E (0.53) ALDH1A1RECQLGAAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US disclosed
US-11242317-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2022-02-08 — — US disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP disclosed
WO-2021028919-A1 METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2021-02-18 — — WO disclosed
CN-105934425-B EBNA1 inhibitors and methods of use thereof 威斯塔解剖学和生物学研究所 2020-08-07 — — CN disclosed
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2020-06-11 — — US disclosed
US-10421718-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-09-24 — — US disclosed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed
WO-2012164085-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-12-06 — — WO disclosed
WO-2009007747-A2 HYDANTOIN DERIVATIVES USED AS MMP12 INHIBITORS ASTRAZENECA AB (SE) 2009-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML NSD2 1042/4885ALDH1A1 3442/4885SMN1; SMN2 3182/4885
US-11242317-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML NSD2 1042/4885ALDH1A1 3442/4885SMN1; SMN2 3182/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 NSD2 580/4885ALDH1A1 4002/4885SMN1; SMN2 2217/4885
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML NSD2 1042/4885ALDH1A1 3442/4885SMN1; SMN2 3182/4885
US-10421718-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML NSD2 1042/4885ALDH1A1 3442/4885SMN1; SMN2 3182/4885
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML NSD2 1042/4885ALDH1A1 3442/4885SMN1; SMN2 3182/4885
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use EBNA1BP2, MLLT1, PML NSD2 1042/4885ALDH1A1 3442/4885SMN1; SMN2 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.